Iovance Biotherapeutics (IOVA) Interest Expenses (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Interest Expenses of $2.6 billion for Q1 2026, up 11634.63% year-over-year from N/an in Q1 2025, and up 66591.24% quarter-over-quarter from $3.9 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Interest Expenses (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Interest Expenses for 16 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 11634.63% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (up 11634.63% YoY), while the FY2025 annual figure was $893.0 million, up 859.42% from the prior year.
- Interest Expenses climbed to $2.6 billion in Q1 2026 per IOVA's latest filing, from $3.9 million in the prior quarter.
- Across five years, Interest Expenses topped out at $2.6 billion in Q1 2026 and bottomed at -$8.6 million in Q4 2023.
- Historically, Interest Expenses has averaged $223.5 million across 5 years, with a median of $22.0 million in 2025.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 19725.6% — and 2024, when it slumped 99.04%.
- Iovance Biotherapeutics' Interest Expenses stood at -$7.3 million in 2022, then slipped by 18.48% to -$8.6 million in 2023, then jumped by 158.53% to $5.0 million in 2024, then decreased by 23.12% to $3.9 million in 2025, then surged by 66591.24% to $2.6 billion in 2026.
- Business Quant data shows IOVA's Interest Expenses at $2.6 billion in Q1 2026, $3.9 million in Q4 2025, and $156.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 4.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Bn |
| Jun 30, 2026 | 4.00 Bn |
| Mar 31, 2026 | 2.58 Bn |
| Mar 31, 2026 | 2.58 Bn |
| Dec 31, 2025 | 3.87 Mn |
| Dec 31, 2025 | 3.87 Mn |
| Sep 30, 2025 | 156.56 Mn |
| Sep 30, 2025 | 156.56 Mn |
| Jun 30, 2025 | 86.37 Mn |
| Jun 30, 2025 | 86.37 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Mar 31, 2025 | 22.00 Mn |
| Dec 31, 2024 | 5.04 Mn |
| Dec 31, 2024 | 5.04 Mn |
| Sep 30, 2024 | 22.70 Mn |
| Sep 30, 2024 | 22.70 Mn |
| Jun 30, 2024 | 6.23 Mn |
| Jun 30, 2024 | 6.23 Mn |
| Mar 31, 2024 | 59.50 Mn |
| Mar 31, 2024 | 59.50 Mn |